A case of avian influenza A(H5N1) in England, January 2022

Isabel Oliver1, Jonathan Roberts2, Colin S Brown1, Alexander MP Byrne3, Dominic Mellon2, Rowena DE Hansen3, Ashley C Banyard4, Joe James5, Matthew Donati2, Robert Porter6, Joanna Ellis1, Jade Cogdale1, Angie Lackenby1, Meera Chand1, Gavin Dabrera1, Ian H Brown3, Maria Zambon1

1. United Kingdom Health Security Agency (UKHSA), London, United Kingdom
2. United Kingdom Health Security Agency (UKHSA), Bristol, United Kingdom
3. Animal and Plant Health Agency (APHA), Weybridge, United Kingdom
4. Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom

Correspondence: Isabel Oliver (isabel.oliver@phe.gov.uk)

On 5 January 2022, high pathogenicity avian influenza A(H5N1) was confirmed in an individual who kept a large flock of ducks at their home in England. The individual remained asymptomatic. H5N1 was confirmed in 19/20 sampled live birds on 22 December 2021. Comprehensive contact tracing (n = 11) revealed no additional primary cases or secondary transmissions. Active surveillance of exposed individuals is essential for case identification. Asymptomatic swabbing helped refine public health risk assessment and facilitated case management given changes in avian influenza epidemiology.

We present a case report of the first confirmed human case of avian influenza A(H5N1) in England in January 2022 following identification of the strain in a duck flock kept at their residence. We describe the clinical epidemiological and virological aspects, and discuss the importance of surveillance through an asymptomatic testing programme.

Case detection and description

An outbreak of high pathogenicity avian influenza (HPAI) H5N1 was confirmed by the United Kingdom (UK) chief veterinary officer in a flock of ca 125 Muscovy ducks in a domestic setting in South West England on 22 December 2021. After the death of one bird on 18 December, followed by additional deaths and clinical signs of illness in the flock on 20 December, 20 Muscovy ducks were sampled on 21 December and samples submitted to the National Reference Laboratory at the Animal and Plant Health Agency (APHA), Weybridge, UK with 19 live birds testing positive for H5N1 HPAI virus.

On confirmation of the avian outbreak, the owner, in their early 80s and who had no signs of infection, was prescribed a prophylactic dose of oseltamivir (75 mg once per day) on 24 December since they had been exposed to infected birds and their secretions without personal protective equipment (PPE). On the same day, a routine nasal swab was collected from the owner as part of the UK Health Security Agency’s (UKHSA) avian influenza surveillance programme, which includes testing of asymptomatic people exposed to the virus. The sample tested positive for influenza A by PCR in two different UKHSA laboratories. Human seasonal influenza viruses, H1 and H3, were not detected by subtyping PCR assays and the circumstances in which the individual resided – close contact with avian influenza H5N1-infected birds, heavily contaminated environment and lack of plausible human contacts for seasonal influenza – led to the individual being managed as a presumptive case of avian influenza A virus. As such, the case was requested to isolate at home and received an extended treatment course of oseltamivir (75 mg twice per day) for 10 days until two consecutive PCR tests were negative at the reference laboratory; the individual remained asymptomatic throughout.

Of note, the affected individual had been vaccinated on 23 November 2021 with the Fluad Tetra vaccine (Seqirus, Maidenhead, UK), containing inactivated influenza virus haemagglutinin and neuraminidase surface antigens.

Virological investigations

The case was re-sampled with nose and throat swabs on 26 and 31 December 2021. Some of the initial PCR assays were positive for influenza A, although the cycle threshold (Ct) values were high (> 30 cycles). The UKHSA respiratory viruses unit re-extracted residual original material from 24, 26 and 31 December in order to concentrate the nucleic acid material several fold
compared with standard processes; both H5 subtyping and influenza A PCR testing was repeated. Independent samples from each date confirmed influenza A and subtyping of H5, all with Ct values in the mid-30s, i.e. close to the limit of detection (40 cycles). Whole genome sequencing (WGS) of the virus strain (A/England/215201407/2021, EPI_ISL_8799552, deposited in GISAID) for influenza A was undertaken directly from human clinical respiratory material from the sample on 26 December, as previously described [1] using the Illumina platform (Illumina, San Diego, California, United States).

The H5N1 HPAI virus from the kept ducks was isolated in embryonated fowls' eggs (A/muscovy duck/England/074477/2021) and WGS was performed (EPI_ISL_8809153). Its genomic sequence shared high homology (98.5–100% across all gene segments) and close phylogenetic relationships (7–11) with those of other H5N1 viruses detected during the ongoing UK and European epizootic in wild birds and poultry (Figure 1).

Sequences of all gene segments from the human virus strain (A/England/215201407/2021) were compared with those of the duck virus (A/muscovy duck/England/074477/2021). Analysis confirmed that the H5N1 in human respiratory material was identical in all segments – at the consensus level – to the avian sequence, apart from four nucleotide (nt) mutations: three synonymous mutations, two in the polymerase basic protein (PB) 2 gene at nt positions 75 and 220, and one in PB1 gene at nt position 1,481. One coding change was noted in polymerase acidic protein (PA) gene arising from a further non-synonymous mutation at nt position 485, resulting in a conservative change from asparagine (N) in the duck sequence to threonine (T) at amino acid position 162 in the human PA sequence. In all other UK H5N1 avian genomes from 2021, there is a T at position 162.

Examination of human H5N1 or H5Nx sequences in GISAID (n=515) indicates that at PA position 162, T occurs in 97.2% while N has not been reported. In more than 9,000 avian H5N1 sequences on GISAID, N is
detected at very low frequency (<1% of sequences), suggesting that this mutation is not associated with H5N1 avian influenza viruses obtained from infected humans. Virus isolation was not possible from the H5N1-containing human materials because the original swab samples were taken into medium containing guanidinium, which inactivates live virus but preserves RNA.

Analyses of the full genome sequence of virus isolated from the ducks (A/muscovy duck/England/074477/2021) was undertaken using an international H5N1 genetic changes inventory [2] and those described by Suttie et al. 2019 [3], to identify mutations that determine viral genetic markers associated with increased virulence, potential adaptation to mammalian species or altered susceptibility to existing antiviral drugs (neuraminidase and ion channel inhibitors). The virus had the same profile as other UK H5N1 avian viruses (Figure 1) with no strong correlates for specific increased affinity for humans and contained no mutations conferring antiviral resistance to oseltamivir or amantadine.

**Public health investigations and control measures**

The public health response was coordinated through an incident management team. Of 11 contacts identified (Table), only one had close contact with the human case without the use of PPE. That contact received post-exposure antiviral prophylaxis (oseltamivir; 75 mg once per day for 10 days), tested negative following asymptomatic swabbing, and completed active monitoring for 10 days without developing symptoms.

The remaining 10 contacts wore PPE during all interactions with the case or the infected premises. All were placed under active monitoring for 10 days and none reported any symptoms. As all were exposed to the contaminated environment, they were offered antiviral chemoprophylaxis and participation in the UKHSA’s asymptomatic testing programme. Swabs were sent out by courier and postal kit; tests rely on self-swabbing and return. Four of 11 were returned and tested negative.

All birds at the infected premises were culled by the APHA on 30 and 31 December 2021. Professional decontamination of the whole premises including the dwelling is being undertaken.

**Epidemiological context**

Wild water birds are the reservoir for avian influenza [4]. Domestic poultry are vulnerable to spill-over infection from migratory wild birds, with outbreaks frequently reported in farm settings including a contemporaneous large outbreak in Great Britain [5]. In Great Britain, the autumn/winter 2021/22 season has seen the largest ever number of HPAI H5N1 wild bird detections and poultry outbreaks since 2003, when this avian virus started to spread from Asia to Europe and Africa. Human avian influenza infections are rare. However, some viruses, such as goose/Guangdong lineage H5Nx or Asian lineage H7N9 viruses, have been associated with human disease with high case fatality rates [6].

Since 2014, over 50 laboratory-confirmed cases of human infection with influenza A(H5N6) virus have been reported from China. The number increased during 2021, with ca 25 cases reported and 10 fatalities, emphasising the continuing high case fatality rate of zoonotic transmissions associated with H5 influenza subtypes. Virological characterisation of recent human zoonotic H5N6 viruses shows that H5N6 Eurasian viruses have a haemagglutinin (HA) protein which groups into clade 2.3.4.4h, which is distinct from the HA of the circulating European viruses, which groups into clade 2.3.3.4b [7]. HPAI H5N6 and H5N8 subtype candidate vaccine viruses have been developed or recommended for pandemic preparedness including clade
asymptomatic swabbing is part of the United Kingdom Health Security Agency surveillance for individuals exposed to an avian influenza virus.

The active monitoring period was 10 days after exposure and consisted of daily checks for the development of any influenza-like symptoms following a potential exposure event. The aim of the asymptomatic testing programme is to ensure timely and effective detection of any possible case of transmission to humans. The programme will also provide intelligence to help refine public health risk assessment and facilitate case and situation management, given these recent changes in avian influenza epidemiology.

In the context of a high prevalence of infection in birds in England, in 2021 UKHSA strengthened its surveillance to include testing of asymptomatic, potentially exposed contacts in addition to those who report symptoms following a potential exposure event. The aim of the asymptomatic testing programme is to ensure timely and effective detection of any possible case of transmission to humans. The programme will also provide intelligence to help refine public health risk assessment and facilitate case and situation management, given these recent changes in avian influenza epidemiology. This case reported no symptoms at any point in time during the event. Seroprevalence studies suggest that subclinical and clinically mild human A(H5N1) virus infections are uncommon [10]. Individuals may have immunity because of prior exposure, or prompt administration of prophylactic antiviral drugs could have tempered disease progression. Focussing testing on people who develop symptoms consistent with influenza will miss some infections, with consequent risk to public health. Testing asymptomatic people accompanied with active surveillance of individuals following a high-risk exposure to the virus without any PPE protection is recommended. Such investigations increase our knowledge of the zoonotic risk posed by influenza A viruses and provide important evidence help strengthen One Health responses, particularly given the unusual infection pressure in avian populations and extensive global spread of this particular strain of H5N1.

This case reported no symptoms at any point in time during the event. Seroprevalence studies suggest that subclinical and clinically mild human A(H5N1) virus infections are uncommon [10]. Individuals may have immunity because of prior exposure, or prompt administration of prophylactic antiviral drugs could have tempered disease progression. Focussing testing on people who develop symptoms consistent with influenza will miss some infections, with consequent risk to public health. Testing asymptomatic people accompanied with active surveillance of individuals following a high-risk exposure to the virus without any PPE protection is recommended. Such investigations increase our knowledge of the zoonotic risk posed by influenza A viruses and provide important evidence help strengthen One Health responses, particularly given the unusual infection pressure in avian populations and extensive global spread of this particular strain of H5N1.

**Ethical statement**

Ethical approval was not required as this work was undertaken as part of public health response to a case of an infectious disease. The case consented to information being shared as part of a case report in the scientific literature.

**Discussion**

We report the first human case of avian influenza A(H5N1) in Europe. Although transmission from birds to humans is rare, there is a risk that these viruses may adapt and become able to infect and gain the ability to spread from person to person, therefore, early identification of human infection is of great public health importance.

In the context of a high prevalence of infection in birds in England, in 2021 UKHSA strengthened its surveillance to include testing of asymptomatic, potentially exposed contacts in addition to those who report symptoms following a potential exposure event. The aim of the asymptomatic testing programme is to ensure timely and effective detection of any possible case of transmission to humans. The programme will also provide intelligence to help refine public health risk assessment and facilitate case and situation management, given these recent changes in avian influenza epidemiology. This case reported no symptoms at any point in time during the event. Seroprevalence studies suggest that subclinical and clinically mild human A(H5N1) virus infections are uncommon [10]. Individuals may have immunity because of prior exposure, or prompt administration of prophylactic antiviral drugs could have tempered disease progression. Focussing testing on people who develop symptoms consistent with influenza will miss some infections, with consequent risk to public health. Testing asymptomatic people accompanied with active surveillance of individuals following a high-risk exposure to the virus without any PPE protection is recommended. Such investigations increase our knowledge of the zoonotic risk posed by influenza A viruses and provide important evidence help strengthen One Health responses, particularly given the unusual infection pressure in avian populations and extensive global spread of this particular strain of H5N1.

**Acknowledgements**

Our sincere thanks to all members of the multidisciplinary incident management team that coordinated and delivered all aspects of testing and care for the individual affected, liaison with the individual and family, avian handling, and site safety and decontamination. We acknowledge colleagues at the UK Health Security Agency Science Group, members of the Respiratory Virus Unit UKHSA Colindale and Public Health laboratories, Specialised Microbiology and Laboratories in Bristol and Manchester for technical support and the South West Health Protection Team. We also acknowledge Scott M Reid, Vivian Coward, Stephanie Meyer and Fabian Z X Lean for technical assistance.

**Table**

Management of contacts exposed to the human case with high pathogenicity avian influenza A(H5N1), England, January 2022 (n = 11)

| Contact exposure | Exposed (n) | Symptomatic (n) | Active monitoring completeda (n) | Prescribed antiviral drugsb (n) | Asymptomatic swabbingc (n) | Test results |
|------------------|------------|----------------|-------------------------------|-------------------------------|---------------------|--------------|
| Without PPE      | 11         | 0              | 11                            | 10                            | 11                  | 4            | NA           |
| With PPE         | 10         | 0              | 10                            | 10                            | 3                   | 1            | Neg.         |

Neg.: negative; PPE: personal protective equipment.

a The active monitoring period was 10 days after exposure and consisted of daily checks for the development of any influenza-like symptoms following a potential exposure event.

b Antiviral drug used was oseltamivir. No monitoring of compliance was conducted.

c Asymptomatic swabbing is part of the United Kingdom Health Security Agency surveillance for individuals exposed to an avian influenza-infected premises.

2.3.4.4b CVV (A/Astrakhan/3212/2020-like) [8]. This is of increased importance given the recent detection of clade 2.3.4.4b viruses in mammals in Europe [9].
We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database on which this research is based (Supplementary Table S1) and analysis described in text. All submitters of the data may be contacted directly via the GISAID website www.gisaid.org.

Funding statement: JJ, APMB, ACB, RH and IHB were part funded by the UK Department for the Environment, Food and Rural Affairs (Defra) and the devolved Scottish and Welsh governments under grants SV3400, SV3006 and SE2213.

Conflict of interest
None declared.

Authors’ contributions
IO, JR, CSB, AMPB, DM, RDEH, ACB, JJ, MD, RP, JE, JC, AL, MC, GD, IHB and MZ contributed to the public health or animal health investigation and response to this case including gathering of information and interpreting data. IO, IB and MZ drafted the manuscript and all authors were involved in revising the manuscript.

References
1. Goldhill DH, Langat P, Xie H, Galano M, Miah S, Kellam P, et al. Determining the mutation bias of favipiravir in influenza virus using next-generation sequencing. J Virol. 2019;93(2):e01217-18. https://doi.org/10.1128/JVI.01217-18 PMID: 30381482
2. United States (US) Centers for Disease Control and Prevention (CDC). H5N1 Genetic Changes Inventory: A Tool for International Surveillance. Atlanta: US CDC; 2012. Available from: https://www.cdc.gov/flu/avianflu/h5n1-genetic-changes.htm
3. Suttie A, Deng YM, Greenhill AR, Dussart P, Horwood PF, Karlsson EA. Inventory of molecular markers affecting biological characteristics of avian influenza A viruses. Virus Genes. 2019;55(6):739-68. https://doi.org/10.1007/s11262-019-01700-z PMID: 31428925
4. Alexander DJ. An overview of the epidemiology of avian influenza. Vaccine. 2007;25(30):5637-44. https://doi.org/10.1016/j.vaccine.2006.10.051 PMID: 17126960
5. Department for Environment, Food and Rural Affairs and Animal and Plant Health Agency. Guidance avian influenza (bird flu). London: gov.uk. [Accessed: 28 Jan 2022]. Available from: https://www.gov.uk/guidance/avian-influenza-bird-flu#latest-situation
6. World Health Organization (WHO). Influenza (avian and other zoonotic). Geneva: WHO;2018. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic)
7. European Food Safety Authority; European Centre for Disease Prevention and Control and European Union Reference Laboratory for Avian Influenza, Adlhoch C, Fusaro A, Gonzales JL, Kuiken T, et al. Avian influenza overview December 2020 - February 2021. EFSA J. 2021;19(3):e06497. PMID: 33717356
8. Floyd T, Banyard AC, Lean FZX, Byrne AMP, Fullick E, Whittard E, et al. Encephalitis and death in wild mammals at a rehabilitation center after infection with highly pathogenic avian influenza A(H5N8) virus, United Kingdom. Emerg Infect Dis. 2021;27(1):2856-63. https://doi.org/10.3201/eid2711.211225 PMID: 34670647
9. Rijk S, Hesselink H, Lollinga P, Wesseling E, Prins P, Weesendorp E, et al. Highly pathogenic avian influenza A(H5N8) virus in wild red foxes, the Netherlands, 2021. Emerg Infect Dis. 2021;27(1):2960-2. https://doi.org/10.3201/eid2711.211226 PMID: 34670656
10. Chen X, Wang W, Wang Y, Lai S, Yang J, Cowling BJ, et al. Serological evidence of human infections with highly pathogenic avian influenza A(H5N1) virus: a systematic review and meta-analysis. BMC Med. 2020;18(1):377. https://doi.org/10.1186/s11606-020-01836-y PMID: 33261599
11. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013;30(4):772-80. https://doi.org/10.1093/molbev/mst010 PMID: 23329690
12. Larsson A. AliView: a fast and lightweight alignment viewer and editor for large datasets. Bioinformatics. 2014;30(22):3276-8. https://doi.org/10.1093/bioinformatics/btu531 PMID: 25095880
13. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol. 2015;32(1):268-74. https://doi.org/10.1093/molbev/msu300 PMID: 25371430
14. Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat Methods. 2017;14(6):587-9. https://doi.org/10.1038/nmeth.4285 PMID: 28481363
15. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: improving the ultrafast bootstrap approximation. Mol Biol Evol. 2018;35(2):518-22. https://doi.org/10.1093/molbev/msx281 PMID: 29077904

License, supplementary material and copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2022.